A case of high‐risk AML in a patient with advanced systemic mastocytosis

Aggressive SM + AML has limited therapeutic options. Even a strong combination of decitabine–venetoclax–midostaurin has a transient effect on AML and a mitigated effect on SM. Larger series are required to identify the best therapeutic strategy. Aggressive SM + AML has limited therapeutic options. E...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical case reports 2023-07, Vol.11 (7), p.e7134-n/a
Hauptverfasser:	Fazio, Manlio, Vetro, Calogero, Markovic, Uroš, Duminuco, Andrea, Parisi, Marina, Maugeri, Cinzia, Mauro, Elisa, Parrinello, Nunziatina Laura, Stagno, Fabio, Villari, Loredana, Triolo, Anna Maria, Stella, Stefania, Palumbo, Giuseppe A., Di Raimondo, Francesco, Romano, Alessandra, Zanotti, Roberta
Format:	Artikel
Sprache:	eng
Schlagworte:	Abdomen advanced systemic mastocytosis (AdvSM) Biopsy Blood Bone marrow Case Report Chemotherapy cladribine concurrent hematologic disease decitabine–venetoclax (DEC‐VEN) HAM regimen Hypotheses Leukemia Liver Medical imaging Medical prognosis Mutation Neutrophils refractory acute myeloid leukemia (R‐AML) Spleen Thrombocytopenia Ultrasonic imaging
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Aggressive SM + AML has limited therapeutic options. Even a strong combination of decitabine–venetoclax–midostaurin has a transient effect on AML and a mitigated effect on SM. Larger series are required to identify the best therapeutic strategy. Aggressive SM + AML has limited therapeutic options. Even a strong combination of decitabine–venetoclax–midostaurin has a transient effect on AML and a mitigated effect on SM. Larger series are required to identify the best therapeutic strategy.
ISSN:	2050-0904 2050-0904
DOI:	10.1002/ccr3.7134